In October 2024, Alpha-9 announced a $175 Million oversubscribed Series C financing, by Lightspeed Venture Partners and Ascenta Capital with participation from top-tier new investor syndicate and existing investors.

Alpha-9 has built a diversified portfolio of clinical and discovery assets across both validated and novel targets. The Series C will fund human studies for the clinical stage assets and advancement of discovery stage assets to clinic-ready development candidates. It will also fund expanded R&D capabilities and continued investment in CMC and supply chain.